Research Paper Volume 15, Issue 16 pp 8258—8274

Figure 6. The role of acetyl-cinobufagin in growth suppression of TNBC in vivo in a human xenograft model established by orthotopically injecting BT-549 cells. (A) BALB/c animals were divided into Control, napabucasin 10 mg/kg, cinobufagin 2.0 mg/kg, acetyl-cinobufagin 1.0 mg/kg, and acetyl-cinobufagin 2.0 mg/kg groups. The cancer volumes were recorded every 2 days and the curve was eventually drawn. (B) Gross view of xenograft tumor tissue. (C) Ultimately, the animals were sacrificed, and the cancer tissue was harvested and weighed. (D) The weight of the animals was recorded during the assay. (E) No histology abnormity was detected by H&E staining of the main organs in the 5 animal groups. (F) Immunohistochemical staining images of the expression of the cellular proliferative biomarker Ki67 in cancer samples. (G) Expression of STAT3- and EMT-related proteins detected by Western blot analysis. Two-way analysis of variance (ANOVA) was used to study the tumor volume and the Student’s t-test was used for others with p-value significant codes: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.